News

Experts remind families of the importance of follow-up visits with the multidisciplinary team during COVID-19.

Resources are discussed, including the Child Neurology Foundation’s telehealth tip sheet, to help families navigate telehealth.

Several spinal muscular atrophy (SMA) resources are suggested to help physicians and families, including Cure SMA and standard of care guidelines.

Discussing the diagnosis of spinal muscular atrophy (SMA) with the family and lining up appointments with the multidisciplinary team to help care for the patient.

Diana Castro, M.D., stresses the value of the initial in-person neurology visit for evaluation of spinal muscular atrophy (SMA) to ensure a correct diagnosis. The next step in the process would be genetic testing.

The signs and symptoms leading a pediatrician to a diagnosis of spinal muscular atrophy (SMA) are discussed.

The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.

Here's what is coming soon to NeurologyLive.

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.

The chief scientific officer of the Parkinson’s Foundation discussed the “PD GENEration” study that offers genetic testing and counseling to 15,000 people with Parkinson disease.

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.

NeurologyLive’s coverage of ACTRIMS Forum 2021 featured a number of insightful conversations with leading experts in multiple sclerosis care.

Researchers from Pavol Jozef Šafárik University, Košice, Slovakia, found that plasma neurofilament light levels predict no evidence of disease activity status as well as NEDA plus brain volume loss status.

With the COVID era changing social environments and interactions, making sure patients can maintain social connections is as important as ever.

Over a 2-year period, SRP-9003 elicited sustained protein expression in muscle tissue and stabilized North Star Assessment for Dysferlinopathies scores.

Neurology News Network for the week ending March 20, 2021.

Researchers used predictive swallowing score to help guide decision making in gastric tube placement.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 19, 2021.

Black patients accounted for 27% of the patients in the COVID-19 CVD Registry but accounted for 31% of the ischemic stroke cases.

If hypertension is the silent killer, then snoring—and its accompanied condition, obstructive sleep apnea—is the loud killer. Raising awareness of OSA on World Sleep Day is of utmost importance.

Researchers also found that compared to direct to CT patients, DTAS patients has lower onset-to-reperfusion and door-to-groin times.

The oral S1P1 modulator joins a number of other agents in its class, and has also been submitted to the European Medicines Agency for approval in the treatment of MS.

A greater proportion of patients identified by newborn screening achieved a greater than 4-point increase in CHOP-INTEND scores during the observation period compared to those clinically diagnosed.

The neurologist from Massachusetts General Hospital discussed when to prescribe disease-modifying therapy and some challenges in caring for patients with RIS.

Researchers found that physical activity as measured by wearable devices was significantly associated with in-person measures of strength and function in patients with CMT.

Episode 7 of the AUPN Leadership Minute features Donald S. Higgins Jr., MD, of the VHA; and Justin C. McArthur, MBBS, MPH, of Johns Hopkins University. [WATCH TIME: 4 minutes]

The findings suggest the externally altered proprioceptive feedback in forced exercises may be increasing cortical engagement.

Diana Castro, M.D., discusses newborn screening for spinal muscular atrophy (SMA) and suggests how to care for patients after the results are received.

Early recognition and referral of a patient with suspected spinal muscular atrophy (SMA) to a neurologist.

Most treatment-emergent adverse events were mild in severity across both studies, with no evidence of renal toxicity, cardiac signals, or deaths.